RARE falls to fresh 52-week low as FDA decision nears

Ultragenyx Pharmaceutical shares slipped and hit a fresh 52-week low ahead of an FDA decision this week on UX111, a one-time gene therapy for Sanfilippo syndrome type A. The stock fell as much as 1.45% intraday.